<DOC>
	<DOCNO>NCT00730392</DOCNO>
	<brief_summary>The investigator hypothesize administration Etanercept child newly diagnose T1DM may able interdict progression T1DM . The aim study evaluate feasibility safety Etanercept administration pediatric patient recently diagnose type 1 DM .</brief_summary>
	<brief_title>Etanercept New Onset Type 1 Diabetes</brief_title>
	<detailed_description>This double-blind randomized 24-week placebo-controlled feasibility safety study . Subjects receive study drug 24- week period , follow 4 12-week wash period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Males female subject T1DM age 318 year Positive GAD 65 and/or islet cell antibody HbA1c diagnosis 6 % Insulin regimen 3 injection insulin daily ( describe ) White blood count 3,00010,000 platelet &gt; 100,000 Normal ALT AST , creatinine &lt; 1.8 mg/dl T1DM duration equal le 4 week Infection require IV antibiotic diagnosis within past 14 day study entry BMI 85th percentile age gender Unstable household Unable provide compliance study drug , insulin study visit , Evidence psychiatric disease potential study subject and/or primary care taker And chronic disease , include additional autoimmune disorder exception euthyroid autoimmune thyroiditis</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Type 1 diabetes , Etanercept , honeymoon period</keyword>
</DOC>